Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Medicine Man Technologies, Inc (OTC: MDCL) Next Super Stock investor conference presentation 9/26/2019 Medicine Man Technologies, Inc (OTC: MDCL) is a returning presenter from last month’s NEXT SUPER STOCK conference. Andy Williams, CEO delivers an […]
CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, providing an update on the company’s drug development pipeline targeting HIV and cancers, based on CytoDyn’s Leronlimab/PRO 140 platform. […]
The Yield Growth Corp. (CSE: BOSS) interview with CEO Penny Green. In the company’s first interview since going public December 14, 2018, Penny Green explain’s the company’s business […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.